CooperVision Announces Seven-Year Results from MiSight Clinical Trial at AAO 2021

Share

Tweet

Share

Share

Email

November 2, 2021

SAN RAMON, Calif. — At the 2021 American Academy of Optometry Meeting in Boston, CooperVision announced the results from its seven-year pivotal clinical trial on MiSight 1 day contact lenses. Ultimately, 12 months after treatment, axial elongation data showed no rebound effect.^1,2†

In the study’s seventh year, participants were transitioned from MiSight 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated “age-normal” levels — not at an accelerated “catch up” rate that would offset prior myopia control gains.^1,2 This indicates no rebound effect.

“Our unparalleled research clearly illustrates the tremendous potential of MiSight 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment.³ With these results, eye care professionals should be even more confident in prescribing MiSight 1 day,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs.

The latest data analysis illustrates that MiSight 1 day offers a highly desired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (8-17).⁴ Because younger children’s myopia progresses faster than older children’s,⁵ introducing MiSight 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.⁴

“We saw these children grow into young adults during their seven years in the study. It is personally, as well as professionally, fulfilling to know that the benefits of treatment are retained. As MiSight 1 day becomes more widely available and as myopia management becomes the standard of care, I hope other eye care professionals will experience that same joy,” said study investigator Nicola Logan, PhD, Professor of Optometry and Physiological Optics, Aston University.

^References

^{† Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.}